AIMD
Ainos, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.60
+2.56%Year over year
Reported trailing growth
- Revenue
- -87.7%
- EBITDA
- +11.7%
- EBIT
- +5.6%
- EPS
- +98.8%
- Free cash flow
- +9.2%
- Operating cash flow
- +9.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -67.2%
- EBITDA
- +1.8%
- EBIT
- -1.1%
- Net income
- +0.6%
- EPS
- —
- Free cash flow
- +20.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026